Ross Ulbricht, the founder of the online drug marketplace Silk Road, received a full and ... college and embraced the political philosophy of Ludwig von Mises, a staunch opponent of ...

Los Angeles’ Democratic Mayor Karen Bass Thursday conceded her Africa trip was “absolutely” a mistake and that she was working to regain the public’s trust after facing backlash for her ...

US President Donald Trump has given a full pardon to Ross Ulbricht, who has been in prison for 12 years for founding the defunct darknet marketplace the Silk Road. “I just called the mother of ...

Performances in N.Y.C. Advertisement Supported by Once used to frequent rejection letters, Blue has become a regular on major stages and is singing the title role in “Aida” at the Metropolitan ...

President Donald Trump announced Tuesday that he had granted a pardon to Ross William Ulbricht, the founder of the Silk Road dark web marketplace. Ulbricht, who was accused of creating the shadowy ...

President Trump announced Tuesday night that he had granted a “full and unconditional” pardon to Ross Ulbricht, founder of the notorious dark website Silk Road. Trump, 78, announced his grant ...

President Trump said Tuesday he had signed a full pardon for Ross Ulbricht, the founder of the scandalous online marketplace Silk Road, fulfilling a campaign promise Trump had made to Libertarian ...

Ulbricht had been serving a life sentence for his role in founding and operating the dark web marketplace Silk Road. As Trump put it in a Truth Social post: "in honor of [his mother Lyn Ulbricht ...

President Donald Trump said Tuesday he issued a pardon for Ross Ulbricht, who was sentenced to life in prison nearly a decade ago for creating the Silk Road, a website law enforcement called the ...

By Aaron Couch Film Editor After more than a decade of inspiring feature films, documentaries, books and podcasts, Silk Road founder Ross Ulbricht will tell his story in an upcoming documentary he ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its ...